$
d2henry Stock

📚 Stock Market Glossary

Clear, beginner-friendly explanations, real-world analogies, and visual formulas for key stock market terminology.

View Mode:
Total 649 terms available

PROTAC (Proteolysis Targeting Chimera)

Corporate & Tech
💡 Key Takeaway: A revolutionary therapeutic modality that binds disease-causing proteins and recruits intracellular ubiquitin ligases to completely degrade and destroy them.
Trash Disposal Tag Analogy: Instead of applying handcuffs to temporarily block a diseased protein, a PROTAC slaps a disposal barcode onto the rogue protein, summoning the cellular garbage truck (proteasome) to shred it permanently.
😎 10-Second Show-off Pro Tip for Friends!
☕ Show-off Tip: 'The hottest frontier in oncology alongside ADCs is PROTAC. Instead of just blocking receptor sites, it recruits the cell’s internal disposal system to completely destroy disease proteins.'

📖 Beginner-Friendly Explanation

STEP 1

Core Concept & Meaning

PROTAC (Proteolysis Targeting Chimera) is a breakthrough therapeutic platform in Targeted Protein Degradation (TPD) that hijacks the body's natural cellular recycling machinery to selectively tag and eliminate disease-causing proteins.

Unlike traditional small molecule inhibitors that merely block an active binding site, a PROTAC acts as a heterobifunctional molecule linking a target protein to an E3 ubiquitin ligase, triggering rapid proteasomal destruction.

STEP 2

Why It Matters & Mechanism

  • Drugging the 'Undruggable': Accesses over 80% of disease-associated proteins that lack conventional catalytic binding pockets.
  • Catalytic Mode of Action: A single PROTAC molecule degrades multiple target proteins sequentially in a catalytic cycle, achieving high potency at low dosages.
  • Overcoming Drug Resistance: Overcomes secondary mutational resistance that frequently defeats traditional kinase inhibitors.
STEP 3

Practical Investment Tips & Pitfalls

Monitor clinical readouts and licensing deals from TPD biotech pioneers (e.g., Arvinas, Kymera Therapeutics) partnered with global pharmaceutical giants. Pay attention to oral bioavailability and ternary complex stability metrics.

📊 PROTAC Ternary Complex Formation & Degradation Kinetic
Ternary Complex = [ Target_Protein ] + [ PROTAC ] + [ E3_Ligase ] → Polyubiquitination → Proteolysis
▶ High ternary complex cooperativity drives efficient catalytic degradation of targeted oncoproteins at sub-nanomolar concentrations.

⚖️ Key Comparison at a Glance

CategoryPROTAC (TPD Platform)Traditional Small Molecule InhibitorADC (Antibody-Drug Conjugate)
Mechanism of ActionDegrades and destroys the target protein entirelyBlocks active binding site temporarilyDelivers cytotoxic warhead via targeted antibody
Target Scope>80% of proteome (including undruggable)<20% of proteome with active pocketsSurface-expressed membrane antigens
AdministrationOral pill development feasiblePredominantly oral pillsIntravenous (IV) infusion
⚔️ Don't Mix These Up! (Head-to-Head Comparison)
VSADC (Antibody-Drug Conjugate)
View ADC→
💡 Crucial Difference: ADCs use antibodies as guided missiles to deliver toxic payloads to cancer cells, whereas PROTACs use intracellular ubiquitin pathways to degrade target proteins.

📌 Practical Market & Real-World Example

Pfizer and Arvinas advanced Vepdegestrant (ARV-471), an oral PROTAC estrogen receptor degrader that eliminates over 90% of mutant ER oncoproteins in resistant breast cancer patients.